We don’t support this browser anymore.
This means our website may not look and work as you would expect. Read more about browsers and how to update them here.

Benitec Biopharma Inc (BNTC) USD0.0001

Sell:$9.30 Buy:$10.75 Change: $0.33 (3.27%)
Market closed |  Prices as at close on 2 December 2024 | Switch to live prices |
Sell:$9.30
Buy:$10.75
Change: $0.33 (3.27%)
Market closed |  Prices as at close on 2 December 2024 | Switch to live prices |
Sell:$9.30
Buy:$10.75
Change: $0.33 (3.27%)
Market closed |  Prices as at close on 2 December 2024 | Switch to live prices |
The selling price currently displayed is higher than the buying price. This can occur temporarily for a variety of reasons; shortly before the market opens, after the market closes or because of extraordinary price volatility during the trading day.

Business summary

Benitec Biopharma Inc is a clinical-stage biotechnology company. The Company is focused on the advancement of novel genetic medicines. Its proprietary Silence and Replace deoxyribonucleic acid (DNA) -directed ribonucleic acid (RNA) interference platform combines RNA interference, or RNAi, with gene therapy to create medicines that simultaneously facilitate sustained silencing of disease-causing genes and concomitant delivery of wildtype replacement genes following a single administration of the therapeutic construct. The Company is developing Silence and Replace-based therapeutics (BB-301) for chronic and life-threatening human conditions including Oculopharyngeal Muscular Dystrophy (OPMD). BB-301 is an adeno-associated viral vector (AAV)-based gene therapy designed to silence the expression of disease-causing genes (to slow, or halt, the underlying mechanism of disease progression) and to simultaneously replace the mutant genes with normal, wildtype genes.

Contact details

Address:
3940 Trust Way
HAYWARD
94545
United States
Telephone:
+1 (510) 7800819
Website:
https://benitec.com/

Important dates

Future events
There are no future events available.
Past events
There are no past events available.

General stock information

Short code:
BNTC
ISIN:
US08205P2092
Market cap:
$234.25 million
Shares in issue:
23.22 million
Sector:
Biotechnology
Exchange:
NASDAQ
Country:
United States
Currency:
US dollar
Indices:
n/a

Key personnel

  • Jerel Banks
    Executive Chairman of the Board, Chief Executive Officer
  • Megan Boston
    Executive Director

Data policy - All information should be used for indicative purposes only. You should independently check data before making any investment decision. HL cannot guarantee that the data is accurate or complete, and accepts no responsibility for how it may be used. Business summary, contact details and key personnel provided by Thomson Reuters. Important dates provided by Digital Look Ltd. General stock information provided by Reuters.

Share

The London Stock Exchange does not disclose whether a trade is a buy or a sell so this data is estimated based on the trade price received and the LSE-quoted mid-price at the point the trade is placed. It should only be considered an indication and not a recommendation.

Trades priced above the mid-price at the time the trade is placed are labelled as a buy; those priced below the mid-price are sells; and those priced close to the mid-price or declared late are labelled 'N/A'.